The CEO said the Redemplo sNDA for severe hyperglyceridemia was filed November 2nd, with approval possible within six months, perhaps in March-April. Redemplo lowered triglycerides by 80% from baseline, is dosed once a quarter, and carries a list price of $45,000 a year.
ARWR · Arrowhead Pharmaceuticals, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 38%
- Last earnings
- Nov 12, 2026
- Latest filing
- 10-K · Nov 12
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Arrowhead Pharmaceuticals targets a potential U.S. SHTG launch in the second quarter of 2027 after reporting fiscal 2026 revenue of $450.8 million and a net loss attributed to the company of $724.2 million.
Arrowhead launched REDEMPLO after November 18, 2025 approval and is preparing a second-quarter 2027 U.S. launch of plozasiran. Phase 3 studies showed 79% and 81% triglyceride reductions; the company raised $930.0 million through convertible notes, stock and pre-funded warrants.
Arrowhead Pharmaceuticals reported 63% quarter-over-quarter growth in new-to-brand REDEMPLO prescriptions, submitted plozasiran’s sNDA for severe hypertriglyceridemia, and established a new $400 million senior secured term loan facility maturing in November 2031.
Arrowhead Pharmaceuticals refinanced its senior secured term loans with Sixth Street, obtaining a fully funded $400.0 million facility maturing November 2, 2031; it has no scheduled amortization and eliminates required revenue and transaction-proceeds sweeps.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Aug 4, 2026TL;DR. Arrowhead reported positive SHASTA-3 and SHASTA-4 Phase 3 topline results supporting a plozasiran sNDA in SHTG, acquired a priority review voucher to accelerate that submission, and continued to expand REDEMPLO's commercial footprint in FCS including EU and Australia approvals, while net loss widened to $194.3M and operating expenses rose year-over-year.
- + SHASTA-3 and SHASTA-4 both met primary and all pre-specified secondary endpoints with 79% and 81% median triglyceride reductions
- + Plozasiran reduced acute pancreatitis events by 78% across SHTG and 100% in the highest-risk subgroup
- + REDEMPLO received marketing authorization in the EU and Australia, expanding approved footprint to five geographies
- + Madrigal license deal brings $25M upfront plus up to $975M in milestones and tiered royalties
- + Cash and investments of approximately $1.6 billion provide funding flexibility
- − Net loss widened to $194.3M ($1.36/share) from $175.2M a year ago
- − Total operating expenses rose ~$52M year-over-year to $245M, with R&D up ~$36M and SG&A up ~$16M
- − Pre-specified MRI-PDFF subgroup showed no statistically significant difference in liver fat between plozasiran and placebo
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Candidate costs | 443.22M | Year Ended September 30, 2026 filing | — |
| Cumulative new to brand REDEMPLO prescriptions | 950 | as of the end of quarter | — |
| Discovery costs | 78.84M | Year Ended September 30, 2026 filing | — |
| More than 640 unique practitioners had prescribed REDEMPLO | 640 | as of the end of quarter | — |
| Total research and development expense, excluding non-cash expense | 683.36M | Year Ended September 30, 2026 filing | — |
| Total selling, general and administrative expense, excluding non-cash expense | 163.24M | Year Ended September 30, 2026 filing | — |
| Amortization of debt issuance costs | 767K | the three months ended June 30, 2026 filing | — |
| Total cash resources | 1.57B | June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARWR
this stock
Arrowhead Pharmaceuticals, Inc.
|
$5.85B | -37.7% | -48.6% | — | 8.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 23
The CEO said the Redemplo sNDA for severe hyperglyceridemia was filed November 2nd, with approval possible within six months, perhaps in March-April. Redemplo lowered triglycerides by 80% from baseline, is dosed once a quarter, and carries a list price of $45,000 a year.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARWR | -13.4% | -28.7% | -41.6% | -30.9% | -37.7% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -4.9% | -19.5% | -32.4% | -22.2% | -38.9% |